Real-time · AI · Cross-signal
Oncopeptides AB just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Oncopeptides AB, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Oncopeptides partners with Veld and Slavpharma to distribute Pepaxti in Africa and Eurasia
Sep 04, 2024•almost 2 years ago
Contract Type
partnership
Biotechnology
Description
Oncopeptides AB has announced a partnership with Veld Pharmaceuticals GmbH and Slavpharma GmbH to commercialize its flagship drug Pepaxti (melphalan flufenamide) in Africa and Eurasia for the treatment of patients with multiple myeloma.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months